GARDian3 trial enrollment and dosing completed (N=63) in less than nine monthsTopline results expected in 2Q27 with BLA to follow by ...

In a phase 2 trial, OCU410, a modifier gene therapy for geographic atrophy secondary to dry age-related macular degeneration, ...

Ocugen has updated its corporate presentation as of March 2026, outlining an aggressive clinical and regulatory roadmap targeting three Biologics License Application submissions in three years for its ...

Steven Pittler, Ph.D., at the University of Alabama at Birmingham has sought to find modifier genes for the hereditary eye disorder retinitis pigmentosa type 59. After onset in one’s late teens, RP59 ...

Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth (31%) versus control at 12 months (p< ...

Add Yahoo as a preferred source to see more of our stories on Google. A genetic eye disorder Ocugen has dosed the first subject in its Phase II/III GARDian3 trial of modifier gene therapy candidate, ...

Ocugen OCGN is building its ocular portfolio around a modifier gene therapy idea: instead of designing a therapy for a single ...

Ocugen (NASDAQ:OCGN) presented top-line 12-month results from its Phase II ArMaDa clinical trial evaluating OCU410, a ...

The biotech aims to quickly bring three gene therapies to market, and overcome the development and commercialization ...

Ocugen OCGN is pushing three retinal gene therapy programs toward late-stage milestones, with multiple data readouts and ...

CHICAGO (Reuters) - Scientists have discovered a genetic mutation linked with colon cancer that may work like a spigot, controlling the number of precancerous growths that develop and determining a ...

BIRMINGHAM, Ala. – Modifier genes add complexity to precision medicine. A modifier gene is one that has genetic variants such as single nucleotide changes that differ from the most common sequence in ...